Informa
主题演讲
Shalini Andersson, PhD
Developing Next Generation Oligonucleotide Therapeutics
开发下一代寡核苷酸疗法
AstraZeneca
Sudhir Agrawal
Chemical Engineering of Oligonucleotides: Applications for RNA Therapeutic
寡核苷酸的化学工程：RNA 疗法的应用
Arnay Sciences
Yuji Nishiuchi, Ph.D.
Peptide and Protein Therapeutics Conjugated with Human N-Linked Glycans
与人类 N 连接聚醣缀合的胜肽和蛋白质疗法
GlyTech, Inc.
Yutaka Okada
RNAi Therapeutics in Japan: Needs and Solutions-An Alnylam Perspective
日本的 RNAi 治疗：需求与解决方案 - Alnylam 视角
Alnylam Japan KK
Leo Qian, PhD
The Endosomal Escape Vehicle Platform of Cyclic Cell-Penetrating Peptides Enhances the Delivery of Oligonucleotides
利用环状细胞穿透胜肽内体逃脱载体 (EEV) 平台改善寡核苷酸递送
Entrada Therapeutics

第一天 -

第一天 -

search
8:00am - 9:00am
报名・咖啡时光
会前研讨会（可选）
Showing 2 of 2 Streams
9:00am - 9:15am
研讨会主持人致词
  • Thomas Rupp - Owner & Principal, Thomas Rupp Consulting, Germany
9:15am - 12:45pm
研讨会・议程

Workshop Description:

This workshop will address different strategies for overcoming manufacturing challenges of synthetic RNA therapeutics. It will also discuss methods for defining CMC control strategies along the development pathway from early clinical development through later stages of development. A variety of different examples and case studies will be presented to give attendees a good understanding of the current bottlenecks, potential solutions and future directions in oligonucleotide CMC and manufacturing.

Who should attend?

Anyone interested in development of oligonucleotide therapeutics; Anyone interested in outsourcing the manufacturing of oligonucleotide therapeutics to a CMO / CRO. This includes R&D Researchers, Manufacturing Personnel, Quality Assurance, Project Management, Business Development and Scientific Management.








  • Thomas Rupp - Owner & Principal, Thomas Rupp Consulting, Germany
9:00am - 9:15am
研讨会主持人致词

Workshop Description:

Peptides fall between small molecules and biologics in terms of molecular weight and size. Additionally, the complexity of peptide therapeutics is increasing with unnatural amino acid substitutions and various covalent modifications (lipidation, PEGylation). This results in analytical challenges! Learn from the experts on strategies and best practices. Hear case studies from companies working in this area.

Who should attend?

Anyone interested in the analysis and bioanalysis of peptide therapeutics. This includes Research scientists, Manufacturing Personnel, Quality Assurance, Project Management, Business Development and Scientific Management

  • Bruce Morimoto, PhD - Vice President, Drug Development, Alto Neuroscience
9:15am - 10:00am
开发合成胜肽纯化方法的课题 – 案例研究说明
  • Alaric Desmarchelier, PhD - Business Development Manager - Peptides, Almac Group
10:00am - 10:45am
胜肽/蛋白质表征方法的最新趋势
  • Michael McGinley - Director, Global Applications, Phenomenex
10:45am - 11:15am
交流/咖啡时光
11:15am - 12:00pm
胜肽制剂开发中的溶解度和物理稳定性课题
  • Juerg Tschopp, PhD - Principal Scientist, Stratum Medical Corporation
12:00pm - 12:45pm
生物分析挑战、最佳实践和案例研究
12:45pm - 1:55pm
研讨会结束并为上午研讨会与会者提供午餐
Showing 1 of 1 Streams
1:55pm - 2:00pm
主席致词
2:00pm - 2:30pm
开发下一代寡核苷酸疗法
  • Shalini Andersson, PhD - Vice President of Oligonucleotide Discovery, AstraZeneca
2:30pm - 3:00pm
寡核苷酸的化学工程：RNA 疗法的应用
  • Sudhir Agrawal - President and Founder, Arnay Sciences
3:00pm - 3:30pm
与人类 N 连接聚醣缀合的胜肽和蛋白质疗法
  • Yuji Nishiuchi, Ph.D. - Director of Research and Development, GlyTech, Inc.
3:30pm - 4:00pm
交流/咖啡时光
4:00pm - 4:30pm
日本的 RNAi 治疗：需求与解决方案 - Alnylam 视角
  • Yutaka Okada - President and Representative Director, Alnylam Japan KK
4:30pm - 5:00pm
利用环状细胞穿透胜肽内体逃脱载体 (EEV) 平台改善寡核苷酸递送
  • Leo Qian, PhD - Co-Founder and Vice President, Discovery Research, Entrada Therapeutics
5:00pm - 5:30pm
发表最新研究成果
5:30pm - 5:35pm
第一天结束
Next第二天

* 活动内容有可能不事先告知作更动及调整。